While UBE2D3 has been described to be an in vitro tumor suppressor for its role in modulating radiosensitivity [71, 72] and proliferation [73], the in vivo data of TCGA suggested that higher UBE2D3 expression predicts poorer clinical outcomes. The gene discussed is UBE2D3; the disease is neoplasm.